NCT06738836View on ClinicalTrials.gov

A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 3, 2024

Primary Completion Date

January 17, 2025

Study Completion Date

January 17, 2025

Conditions
Healthy Volunteer
Interventions
DRUG

[14C]-EDG-7500

Oral liquid suspension

Trial Locations (1)

21201

Pharmaron Clinical Pharmacology Center, Inc., Baltimore

Sponsors
All Listed Sponsors
lead

Edgewise Therapeutics, Inc.

INDUSTRY